RPT-ORIC® PHARMACEUTICALS ANNOUNCES INITIATION OF HIMALAYAS-1 PHASE 3 TRIAL IN MCRPC EVALUATING RINZIMETOSTAT IN COMBINATION WITH NUBEQA® (DAROLUTAMIDE), SUPPORTED BY CLINICAL COLLABORATION WITH BAYER

Reuters · 1d ago

Please log in to view news